Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Subscribe To Our Newsletter & Stay Updated
